News

Sarepta Therapeutics announces initiation of EMBARK, a global p0ivotal study of SRP-9001, gene therapy for the treatment of DMD (Duchenne Muscular Dystrophy) Original press release > [...]

Sarepta Therapeutics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy, SRP-9001, demonstrates robust expression and consistent safety profile using Sarepta’s [...]

Sarepta Therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51 Results suggest a highly [...]

Sarepta Therapeutics announces FDA approval of AMONDYS 45 (casimersen) injection to treat Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 45. Feb. 25, 2021, >Original [...]

Pfizer doses the first participant in phase 3 study for Duchenne muscular dystrophy (DMD) investigational gene therapy. January 07, 2021, > Original press release < Pfizer Inc. announced [...]

Catabasis Pharmaceuticals announces top-line results for the phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy.   PolarisDMD Trial Did Not Achieve Primary or Secondary [...]

Santhera to discontinue Phase 3 SIDEROS study and development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and focus on vamorolone. Original Press Release > Pratteln, Switzerland, October [...]

Pfizer receives FDA fast track designation for Duchenne muscular dystrophy (DMD) investigational gene therapy. Official press release > NEW YORK–(BUSINESS WIRE) Pfizer Inc. announced [...]

La Force is happy to share the latest edition of the Catabasis Connection newsletter – Communicating clinical trial results. Catabasis understands the importance of clearly communicating [...]

Santhera exercises option to obtain worldwide rights of Vamorolone for Duchenne muscular dystrophy (DMD) and All Other Indications La Force is happy to share this press release provided [...]